- Home
- GERN vs ATLC Comparison
GERN vs ATLC Comparison
Compare GERN & ATLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GERN | ATLC |
|---|---|---|
| Founded | 1990 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.3M | 816.9M |
| IPO Year | 1996 | 1999 |
Fundamental Metrics
Financial Performance| Metric | GERN | ATLC |
|---|---|---|
| Price | $1.38 | $66.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $3.00 | ★ $87.50 |
| AVG Volume (30 Days) | ★ 6.8M | 82.1K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.57 |
| EPS | N/A | ★ 5.63 |
| Revenue | $183,403,000.00 | ★ $498,496,000.00 |
| Revenue This Year | $147.34 | $403.57 |
| Revenue Next Year | $39.11 | $60.82 |
| P/E Ratio | ★ N/A | $11.82 |
| Revenue Growth | ★ 522.13 | 33.26 |
| 52 Week Low | $1.04 | $41.37 |
| 52 Week High | $4.05 | $78.91 |
Technical Indicators
Market Signals| Indicator | GERN | ATLC |
|---|---|---|
| Relative Strength Index (RSI) | 64.29 | 69.37 |
| Support Level | $1.21 | $58.08 |
| Resistance Level | $1.42 | $68.99 |
| Average True Range (ATR) | 0.07 | 2.39 |
| MACD | 0.02 | 1.15 |
| Stochastic Oscillator | 85.48 | 82.53 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.